Date	Firm	Action	Rating
May 20, 2026	HC Wainwright & Co.	DOWNGRADE	Buy → Neutral
Apr 9, 2026	Ascendiant Capital	MAINTAIN	Buy → Buy
Jan 27, 2026	HC Wainwright & Co.	MAINTAIN	Buy → Buy
Nov 28, 2025	Ascendiant Capital	MAINTAIN	Buy → Buy

Earnings Estimates

Period	EPS Est.	Range	Growth	#
Current Q	$-0.78 ▲ +60.2%	$-0.78 — $-0.78	82% YoY	1
Next Q	$-0.79 ▲ +59.7%	$-0.79 — $-0.79	69% YoY	1
Current FY	$-3.18 ▲ +59.6%	$-3.18 — $-3.18	71% YoY	1
Next FY	$-0.70 ▲ +67.6%	$-0.70 — $-0.70	78% YoY	1

Latest Reports

BEARISH PRESS-RELEASE 6/10

Sixty Degrees Pharmaceuticals reported Q1 2026 revenue of $162K (down ~1% YoY) and a net loss of $1.28 per share, signif

May 15, 2026

MIXED Press 5/10

Sixty Degrees Pharmaceuticals reported FY2025 net product revenue growth of 65% to $1.005 million, driven by higher sale

Mar 31, 2026

Reddit Sentiment

60°

Warm

Bearish Neutral Bullish

1 mentions 1 bullish 0 bearish

∅

No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.

∅

No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.

1 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 0 neutral. Avg impact: 6.0/10.

BEARISH PRESS-RELEASE 6/10

Sixty Degrees Pharmaceuticals reported Q1 2026 revenue of $162K (down ~1% YoY) and a net loss of $1.

May 15, 2026

MIXED 5/10

Sixty Degrees Pharmaceuticals reported FY2025 net product revenue growth of 65% to $1.005 million, d

Mar 31, 2026

NEUTRAL 4/10

Sixty Degrees Pharmaceuticals submitted a New Dietary Ingredient Notification (NDIN) to the FDA for

Mar 18, 2026

Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$4.20 mean target +202.2% upside Strong Buy (3.00)

$4.20 Low $4.20 High

Metric	Value
Current Price	$1.39
Target Low	$4.20
Target Mean	$4.20
Target Median	$4.20
Target High	$4.20
# Analysts	1
Recommendation	Strong Buy (3.00)

Earnings Estimates & Revisions

Period	EPS Avg	EPS Low	EPS High	EPS Growth	30d Rev.	Up/Down	Rev. Avg	Rev. Growth	Analysts
Current Q 2026-06-30	$-0.78	$-0.78	$-0.78	82.0%	+60.2%	1↑ 0↓	$0.0B	29.9%	1
Next Q 2026-09-30	$-0.79	$-0.79	$-0.79	68.8%	+59.7%	1↑ 0↓	$0.0B	-5.4%	1
Current FY 2026-12-31	$-3.18	$-3.18	$-3.18	71.4%	+59.6%	1↑ 0↓	$0.0B	79.0%	1
Next FY 2027-12-31	$-0.70	$-0.70	$-0.70	78.0%	+67.6%	1↑ 0↓	$0.0B	-33.3%	1

Current Quarter EPS Revision History

Timepoint	EPS Estimate	Change
Current	$-0.780
7d ago	$-1.960	+1.180
30d ago	$-1.960	+1.180
60d ago	$-1.960	+1.180
90d ago	$-1.960	+1.180

2 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.

Individual Analyst Actions

Date	Analyst Firm	Action	Previous Rating	New Rating
May 20, 2026	HC Wainwright & Co.	DOWNGRADE	Buy	Neutral
Apr 9, 2026	Ascendiant Capital	MAINTAIN	Buy	Buy
Jan 27, 2026	HC Wainwright & Co.	MAINTAIN	Buy	Buy
Nov 28, 2025	Ascendiant Capital	MAINTAIN	Buy	Buy

Monthly Consensus History

Period	Strong Buy	Buy	Hold	Buy %
May 1, 2026	2	5	1	88%
Apr 1, 2026	2	5	1	88%
Mar 1, 2026	2	5	1	88%
Feb 1, 2026	2	5	1	88%
Jan 1, 2026	2	5	1	88%

Strong BuyBuyHoldSellStrong Sell

∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

60°

Warm

Bearish Neutral Bullish

1 mentions 1 bullish 0 bearish 1 time period

Reddit Sentiment History

Date	Mentions	Sentiment	Bullish	Bearish	Threads
Jan 26, 2026	1	60° Warm	1	0	1

Recent Reddit Threads

r/stockmarket Bullish 3mo ago

SXTP surges on partnership news but faces Nasdaq compliance challenges

▲ 0 💬 0

May 15, 2026

earnings

60 Degrees Pharmaceuticals Announces First Quarter 2026 Results

Apr 17, 2026

Clinical Trial

Long-Term Safety Study of Tafenoquine

Phase Phase 2 — COMPLETED

Apr 15, 2026

other

60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website

ARAKODA® now available via Runway Health, enabling U.S. travelers to access once-weekly malaria prevention through a convenient telehealth platform.

Mar 31, 2026

earnings

60 Degrees Pharmaceuticals Announces 2025 Annual Results

60 Degrees Pharma (Nasdaq: SXTP) FY25 revenue +65% to $1.0M; improved net loss; continued clinical, commercial, and partnership momentum.

Mar 18, 2026

regulatory

60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

60 Degrees files NDIN with FDA for Australian Chestnut Extract; May 25 decision deadline. FSU capsule license option expands commercialization strateg

Mar 12, 2026

short_interest

FTD: SXTP — 510,466 shares ($1.6M) failed to deliver

Settlement: 20260312, Price: $3.22, FTD Value: $1,643,700.52, 60 DEGREES PHARMACEUTICALS INC

Mar 11, 2026

other

60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial

All three patients in 60 Degrees Pharma’s expanded access study were cured of relapsing babesiosis after tafenoquine treatment, supporting guideline r